Peptide Research Database

Growth Factors & Signaling

For Research Use Only. Not for Human or Veterinary Use.

Overview

Growth-hormone secretagogues and GHRH-receptor agonists — ghrelin-receptor peptides, the oral non-peptide secretagogue MK-677, and long- and short-acting GHRH analogues, with a comparison page.

CompoundClassMechanismPrimary research targets
MK-677 (Ibutamoren)Non-peptide GHSR agonistGHSR-1a agonist (non-peptide)Muscle growth, bone density, appetite
IpamorelinPentapeptide GHSR agonistSelective GHSR agonistGH release, muscle repair, metabolism
GHRP-2Hexapeptide GHSR agonistPotent GHSR agonistGH pulse amplification, catabolic states
GHRP-6Hexapeptide GHSR agonistFirst-generation GHRPGH secretion, appetite stimulation
CJC-1295GHRH analogue (DAC)GHRH analogue (DAC technology)Sustained GH / IGF-1 elevation
SermorelinGHRH(1–29) fragmentGHRH(1–29) fragmentGH-deficiency and diagnostic research

How Growth Signaling Peptides Work

Two receptor families dominate here. Ghrelin-receptor (GHSR-1a) agonists — the GHRPs, the selective peptide Ipamorelin and the oral non-peptide MK-677 — mimic ghrelin to trigger pulsatile growth-hormone release through Gαq and calcium signalling. GHRH-receptor agonists — Sermorelin (short-acting) and CJC-1295 (long-acting, DAC) — act like GHRH itself through Gαs and cAMP. A recurring research theme is pairing the two families for complementary GH release.

1. Growth-hormone-secretagogue (GHSR) pathway

MK-677, Ipamorelin and the GHRPs bind GHSR-1a (the ghrelin receptor), stimulating pituitary GH release via Gαq/Ca²⁺, while enhancing GHRH and inhibiting somatostatin.

2. GHRH-receptor pathway

CJC-1295 and Sermorelin activate the GHRH receptor (Gαs/cAMP), amplifying the amplitude and frequency of endogenous GH pulses.

3. GH → IGF-1 axis

All secretagogues raise circulating GH, which drives hepatic IGF-1 and downstream anabolic effects while preserving pulsatility.

Key Properties at a Glance

CompoundCAS numberMW (Da)LengthMechanismHalf-life
MK-677 (Ibutamoren)159634-47-0528.66— (non-peptide)GHSR-1a agonist (non-peptide)~ 24 h
Ipamorelin170851-70-4711.865 aaSelective GHSR agonist~ 2 h
GHRP-2158861-67-7≈ 817.96 aaPotent GHSR agonist~ 30 min
GHRP-687616-84-0873.016 aaFirst-generation GHRP~ 30 min
CJC-1295863288-34-8≈ 3647 (DAC)29–30 aaGHRH analogue (DAC technology)~ 6–8 days
Sermorelin86168-78-7≈ 3357.929 aaGHRH(1–29) fragment~ 12 min

Research Evidence Summary

Representative reported findings from the literature (qualitative). See each compound page for detail.

CompoundKey reported findingReference
MK-677Increased 24-h GH and IGF-1Chapman IM et al.
MK-677Increased lean mass and bone density over 2 yearsNass R et al., 2008
MK-677Preserved GH pulsatility with oral, once-daily dosingMK-677 literature
IpamorelinPotent, selective GH release with minimal prolactin/cortisolRaun K et al.
IpamorelinBone-formation markers in ovariectomized modelsGH-secretagogue literature
GHRP-2Strong GH pulse amplification (high potency)Bowers CY et al.
GHRP-2Used as a GH-reserve diagnostic probeGHRP-2 clinical literature
GHRP-6First peptide GH secretagogue shown to be orally activeBowers CY et al.
GHRP-6Strong ghrelin-appetite signallingGHRP-6 literature
CJC-1295Sustained GH/IGF-1 elevation over several daysTeichman SL et al., 2006
CJC-1295DAC albumin binding extends half-life to ~6–8 daysGHRH-analogue literature
SermorelinReliable GH release; used in GH-deficiency testingGHRH literature
SermorelinPhysiological, short-acting GHRH-receptor probeGHRH literature

Research Dosing Overview

Typical research dose ranges from the literature (for research reference only, not human dosing guidance):

CompoundResearch doseRouteFrequencyDuration
MK-677 (Ibutamoren)10–25 mgOralDaily12–52 wk
Ipamorelin200–500 µgSC2–3×/day8–16 wk
GHRP-2100–300 µgSC2–3×/day8–16 wk
GHRP-6100–300 µgSC2–3×/day8–16 wk
CJC-12951–2 mgSCEvery 5–8 d8–16 wk
Sermorelin200–500 µgSC / IVDaily12–24 wk

Formulation & Reconstitution

FactorRecommendation
SolventBacteriostatic water (0.9% benzyl alcohol)
Reconstitution1–2 mL per vial (peptide-dependent)
Storage (lyophilized)−20°C, desiccated, protected from light
Storage (reconstituted)2–8°C for up to 7–14 days
pH stability range5.0–7.0
Oxidation-sensitive residuesProtect Met / Cys peptides from air and light; add antioxidant where relevant

Selected References

  • Bowers CY. Growth-hormone-releasing peptide (GHRP) foundational literature.
  • Raun K, et al. Ipamorelin, a selective GH secretagogue. European Journal of Endocrinology.
  • Teichman SL, et al. Long-acting GHRH analogue CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
  • Nass R, et al. Oral ghrelin mimetic MK-677 and body composition. Annals of Internal Medicine, 2008.

Need research-grade peptides?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote